Citi: 2026 National Medical Insurance Drug List Negotiation Results Released; Pharmaceutical Companies Say Price Cuts Are Moderate and Controllable

date
09:52 20/11/2026
avatar
GMT Eight
Citi noted that JW Therapeutics' CAR-T product relma-cel entered the national medical insurance list at a price of RMB288,600.
Citi released a research report stating that the National Healthcare Security Administration has completed the 2026 National Reimbursement Drug List (NRDL) negotiations. A total of 107 drugs were newly included in the list this year, including 51 innovative drugs, from companies such as INNOVENT BIO (01801), HUTCHMED (00013), Kelun-Biotech (06990), 3SBIO (01530), ASCENTAGE (06855), JUNSHI BIO (01877), EVEREST MED (01952), CSPC PHARMA (01093), HANSOH PHARMA (03692), SBP GROUP (01177), Shanghai Fosun Pharmaceutical (02196), and CMS (00867). Meanwhile, 34 drugs were removed from the list due to reasons including limited clinical value, the availability of better alternatives, or insufficient necessary information in the drug labeling. The new list has a net increase of 78 product specifications, bringing the total number of drugs on the list to 3,331, with 1,935 western medicines and 1,396 Chinese patent medicines. Citi noted that JW Therapeutics' (02126) CAR-T product relma-cel entered the NRDL at a price of RMB288,600. The commercial insurance innovative drug list newly included 12 drugs, including CAR-T. Although most post-negotiation drug prices have not yet been disclosed, most pharmaceutical companies the bank has engaged with have guided to moderate and controllable price cuts; the new list will take effect from January 1, 2027, and the bank will monitor the final tender prices after implementation.